KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for West Pharmaceutical Services (WST) over the last 17 years, with Q3 2025 value amounting to $75.3 million.

  • West Pharmaceutical Services' Other Non-Current Liabilities rose 1272.46% to $75.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $75.3 million, marking a year-over-year increase of 1272.46%. This contributed to the annual value of $62.2 million for FY2024, which is 632.48% up from last year.
  • According to the latest figures from Q3 2025, West Pharmaceutical Services' Other Non-Current Liabilities is $75.3 million, which was up 1272.46% from $70.4 million recorded in Q2 2025.
  • Over the past 5 years, West Pharmaceutical Services' Other Non-Current Liabilities peaked at $75.3 million during Q3 2025, and registered a low of $27.8 million during Q3 2021.
  • Moreover, its 5-year median value for Other Non-Current Liabilities was $55.1 million (2023), whereas its average is $51.0 million.
  • As far as peak fluctuations go, West Pharmaceutical Services' Other Non-Current Liabilities tumbled by 4059.83% in 2021, and later soared by 6253.69% in 2023.
  • Over the past 5 years, West Pharmaceutical Services' Other Non-Current Liabilities (Quarter) stood at $38.2 million in 2021, then surged by 35.08% to $51.6 million in 2022, then increased by 13.37% to $58.5 million in 2023, then rose by 6.32% to $62.2 million in 2024, then rose by 21.06% to $75.3 million in 2025.
  • Its Other Non-Current Liabilities was $75.3 million in Q3 2025, compared to $70.4 million in Q2 2025 and $65.7 million in Q1 2025.